Melinda Fitzgerald Selected Research

YM 872

10/2019	Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
2/2017	Delayed treatment of secondary degeneration following acute optic nerve transection using a combination of ion channel inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melinda Fitzgerald Research Topics

Disease

10	Optic Nerve Injuries 01/2020 - 11/2007
7	Wounds and Injuries (Trauma) 10/2018 - 01/2013
2	Multiple Sclerosis 11/2021 - 09/2019
2	Demyelinating Diseases (Demyelinating Disease) 11/2021 - 09/2019
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2020 - 01/2014
2	Stroke (Strokes) 01/2016 - 09/2015
2	Brain Injuries (Brain Injury) 05/2008 - 11/2007
1	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2022
1	Gliosis 11/2021
1	Neuroinflammatory Diseases 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Cysts 01/2020
1	Breast Neoplasms (Breast Cancer) 10/2019
1	Brain Concussion (Cerebral Concussion) 10/2018
1	Seroma 02/2017
1	Infections 02/2017
1	Reinjuries 01/2017
1	Skull Fractures (Skull Fracture) 01/2017
1	Nervous System Diseases (Neurological Disorders) 09/2015
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2015
1	Retinal Degeneration 01/2014
1	Glaucoma 03/2010
1	Hypertrophy 02/2010
1	Necrosis 11/2009
1	Inflammation (Inflammations) 01/2009

Drug/Important Bio-Agent (IBA)

6	Ion Channels (Ion Channel)IBA 01/2020 - 02/2017
5	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2008
3	Myelin Basic ProteinIBA 01/2020 - 02/2010
3	lomerizineIBA 10/2019 - 11/2009
2	LipidsIBA 04/2022 - 01/2021
2	CuprizoneIBA 11/2021 - 09/2019
2	YM 872IBA 10/2019 - 02/2017
2	salicylhydroxamic acid (SHAM)IBA 10/2018 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 07/2018 - 01/2017
1	CopperIBA 11/2021
1	PowdersIBA 11/2021
1	Chelating AgentsIBA 11/2021
1	IronIBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020
1	Pharmaceutical PreparationsIBA 10/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2019
1	hydroxyethyl methacrylate (HEMA)IBA 10/2019
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 07/2018
1	Retinaldehyde (Retinal)IBA 01/2018
1	2',3'-dialdehyde ATPIBA 02/2017
1	Neuroprotective AgentsIBA 02/2017
1	AMPA Receptors (AMPA Receptor)IBA 02/2017
1	Purinergic P2X7 ReceptorsIBA 02/2017
1	Malondialdehyde (Propanedial)IBA 01/2017
1	TubulinIBA 01/2017
1	Amyloid (Amyloid Fibrils)IBA 01/2017
1	methyl-lysineIBA 01/2017
1	AntioxidantsIBA 01/2016
1	Glutamic Acid (Glutamate)FDA Link 09/2015
1	Glucose (Dextrose)FDA LinkGeneric 09/2015
1	Oxygen (Dioxygen)IBA 09/2015
1	Peptides (Polypeptides)IBA 09/2015
1	Arginine (L-Arginine)FDA Link 09/2015
1	CalciumIBA 01/2015
1	8-hydroxyguanosineIBA 01/2014
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 03/2010
1	Caspase 3 (Caspase-3)IBA 11/2009
1	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2009
1	MineralocorticoidsIBA 01/2009
1	GlucocorticoidsIBA 01/2009
1	Low Density Lipoprotein Receptor-Related Protein-2IBA 11/2007
1	MetallothioneinIBA 11/2007

Therapy/Procedure

4	Therapeutics 02/2017 - 01/2013
3	Lasers (Laser) 01/2016 - 01/2014
1	Intraperitoneal Injections 10/2019
1	Oral Administration 10/2019
1	Treatment Delay 02/2017
1	Phototherapy (Light Therapy) 03/2015